Corcept Therapeutics (NASDAQ:CORT) CFO Atabak Mokari Sells 40,000 Shares of Stock

Posted by on Jun 4th, 2026

Corcept Therapeutics Incorporated (NASDAQ:CORT – Get Free Report) CFO Atabak Mokari sold 40,000 shares of Corcept Therapeutics stock in a transaction dated Monday, June 1st. The stock was sold at an average price of $70.00, for a total value of $2,800,000.00. Following the completion of the sale, the chief financial officer directly owned 15,257 shares of the company’s stock, valued at approximately $1,067,990. This trade represents a 72.39% decrease in their position. The sale was disclosed in a legal filing with the SEC, which can be accessed through the SEC website. The sale was made to cover tax withholding obligations related to the vesting of equity awards.

Corcept Therapeutics Stock Performance

Shares of NASDAQ CORT opened at $72.65 on Thursday. Corcept Therapeutics Incorporated has a fifty-two week low of $28.66 and a fifty-two week high of $91.00. The stock has a market cap of $7.80 billion, a PE ratio of 207.58 and a beta of 0.50. The stock has a fifty day moving average of $50.26 and a 200-day moving average of $52.01.

Corcept Therapeutics (NASDAQ:CORT – Get Free Report) last announced its quarterly earnings results on Thursday, April 30th. The biotechnology company reported ($0.30) EPS for the quarter, missing the consensus estimate of ($0.11) by ($0.19). The firm had revenue of $164.90 million during the quarter, compared to the consensus estimate of $185.83 million. Corcept Therapeutics had a net margin of 6.14% and a return on equity of 7.40%. The firm’s revenue for the quarter was up 4.9% on a year-over-year basis. During the same period in the previous year, the business earned $0.17 earnings per share. On average, sell-side analysts predict that Corcept Therapeutics Incorporated will post 0.53 EPS for the current year.

Institutional Trading of Corcept Therapeutics

A number of hedge funds and other institutional investors have recently bought and sold shares of the stock. Torren Management LLC purchased a new position in Corcept Therapeutics in the 4th quarter worth approximately $25,000. Advisory Services Network LLC purchased a new stake in shares of Corcept Therapeutics during the 3rd quarter worth approximately $25,000. Clearstead Advisors LLC raised its holdings in Corcept Therapeutics by 163.6% during the 3rd quarter. Clearstead Advisors LLC now owns 311 shares of the biotechnology company’s stock valued at $26,000 after buying an additional 193 shares during the period. Atlas Capital Advisors Inc. purchased a new stake in Corcept Therapeutics during the 4th quarter valued at $31,000. Finally, State of Wyoming raised its holdings in Corcept Therapeutics by 29.5% during the 1st quarter. State of Wyoming now owns 816 shares of the biotechnology company’s stock valued at $33,000 after buying an additional 186 shares during the period. Hedge funds and other institutional investors own 93.61% of the company’s stock.

Analyst Ratings Changes

CORT has been the subject of a number of recent research reports. Truist Financial upgraded Corcept Therapeutics to a “strong-buy” rating in a research report on Wednesday, March 25th. Wolfe Research upgraded Corcept Therapeutics from an “underperform” rating to a “peer perform” rating in a research report on Thursday, March 26th. UBS Group set a $135.00 price target on shares of Corcept Therapeutics in a research note on Thursday, May 28th. Zacks Research raised Corcept Therapeutics from a “strong sell” rating to a “hold” rating in a research report on Monday, May 4th. Finally, HC Wainwright upped their price target on shares of Corcept Therapeutics from $75.00 to $95.00 and gave the stock a “buy” rating in a research note on Tuesday. One analyst has rated the stock with a Strong Buy rating, four have issued a Buy rating and three have assigned a Hold rating to the company’s stock. According to MarketBeat, the company has a consensus rating of “Moderate Buy” and a consensus price target of $88.83.

View Our Latest Stock Analysis on CORT

Corcept Therapeutics Company Profile

(Get Free Report)

Corcept Therapeutics is a clinical-stage biopharmaceutical company focused on discovering and developing drugs that modulate the effects of cortisol, a hormone implicated in a range of severe metabolic, oncologic and psychiatric disorders. The company’s scientific platform centers on selectively targeting the glucocorticoid receptor to counteract the harmful consequences of excess cortisol, a strategy designed to address diseases with significant unmet medical needs.

The company’s flagship marketed product, Korlym (mifepristone), is approved in the United States for the treatment of hyperglycemia secondary to Cushing’s syndrome in patients who have type 2 diabetes or glucose intolerance and are not candidates for surgery.

Featured Articles

Insider Buying and Selling by Quarter for Corcept Therapeutics (NASDAQ:CORT)

Receive News & Ratings for Corcept Therapeutics Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Corcept Therapeutics and related companies with MarketBeat.com's FREE daily email newsletter.